Literature DB >> 3948307

Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line.

B Hartley-Asp, P O Gunnarsson, J Liljekvist.   

Abstract

Prednimustine and chlorambucil induce dose- and time-dependent cell death in V79 Chinese hamster cells in vitro. Prednimustine was found to be 3-4 times more potent than either chlorambucil or an equimolar mixture of its components chlorambucil and prednisolone after 24 h treatment. Prednimustine was hydrolyzed to prednisolone and chlorambucil in the system, and the concentration of prednimustine was reduced by one half within 15 h. Prednisolone was not further metabolized, but chlorambucil was rapidly inactivated by dechlorination, the half-life being 2.5 h. No dechlorinated prednimustine was formed during the experiments. The higher stability of prednimustine than chlorambucil is probably due to protective binding to different serum proteins from those that bind chlorambucil. Substitution of fetal calf serum by human serum albumin revealed that hydrolysis of prednimustine is catalyzed by esterases present in the serum. In similar substitution experiments cell survival studies indicated that prednimustine itself was not cytotoxic. Rather, cytotoxicity was found to correlate with hydrolysis to chlorambucil. Thus, it appears that the prolonged availability of chlorambucil is responsible for the increased potency of prednimustine in this system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948307     DOI: 10.1007/bf00256154

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  A solubilizable acrylamide gel for electrophoresis.

Authors:  H S. Anker
Journal:  FEBS Lett       Date:  1970-04-16       Impact factor: 4.124

2.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

3.  Therapeutic effect of Leo 1031, an alkylating corticosteroid ester, in lymphoproliferative disorders. I. chronic lymphocytic leukaemia.

Authors:  L Brandt; I Kónyves; T R Móller
Journal:  Acta Med Scand       Date:  1975-04

4.  The pharmacokinetics of prednimustine and chlorambucil in the rat.

Authors:  D R Newell; C R Shepherd; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Mammary tumour inhibition and subacute toxicity in rats of prednimustine and of its molecular components chlorambucil and prednisolone.

Authors:  B Fredholm; K Gunnarsson; G Jensen; J Müntzing
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-03

6.  Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

Authors:  D R Newell; A H Calvert; K R Harrap; T J McElwain
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

7.  Lipophilic drugs and lipoproteins: partitioning effects on chloroethylnitrosourea reaction rates in serum.

Authors:  R J Weinkam; A Finn; V A Levin; J P Kane
Journal:  J Pharmacol Exp Ther       Date:  1980-08       Impact factor: 4.030

8.  A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer.

Authors:  J Løber; H T Mouridsen; I E Christiansen; P Dombernowsky; W Mattsson; M Rørth
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

9.  Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone.

Authors:  K Ideström; E Kimby; M Björkholm; H Mellstedt; L Engstedt; G Gahrton; B Johansson; D Killander; K H Robérts; A M Stalfelt; A M Udén; B Wadman; S Wählby
Journal:  Eur J Cancer Clin Oncol       Date:  1982-11

10.  Interaction of human serum albumin with anticancer agents in vitro.

Authors:  I Takahashi; T Ohnuma; S Kavy; S Bhardwaj; J F Holland
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640

View more
  8 in total

1.  Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.

Authors:  Shengtao Xu; Lingling Pei; Chengqian Wang; Yun-Kai Zhang; Dahong Li; Hequan Yao; Xiaoming Wu; Zhe-Sheng Chen; Yijun Sun; Jinyi Xu
Journal:  ACS Med Chem Lett       Date:  2014-05-28       Impact factor: 4.345

2.  Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.

Authors:  M M Oppitz; E Musch; M Malek; H P Rüb; G E von Unruh; U Loos; B Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

Authors:  E Musch; M Malek; J Peter-Katalinic; H Egge; H Rink; B Lathan; E Riedel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria.

Authors:  D R Gandara; C B George; C A Ries; M M Koretz; J P Lewis
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.

Authors:  L Bastholt; C J Johansson; P Pfeiffer; L Svensson; S A Johansson; P O Gunnarsson; H Mouridsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Assembly of prednimustine low-density-lipoprotein complexes and their cytotoxic activity in tissue culture.

Authors:  B Lundberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity.

Authors:  M E O'Brien; D M Eccles; S G Allen; G Knight; A Rodger; U Chetty; J F Smyth; R C Leonard
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.

Authors:  R C Leonard; G E Smart; J R Livingstone; M A Cornbleet; G R Kerr; S Fletcher; J N Webb; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.